Staying updated with clinical guidelines is crucial, but translating them into daily practice can be a challenge. The 2022 American Association for the Study of Liver Diseases (AASLD) practice guidance on Drug-Induced Liver Injury (DILI) is a landmark document. To make it instantly actionable, we've distilled its core principles into a clear, concise...
The "5 Rights of Medication Administration" are a fundamental framework in patient safety designed to prevent medication errors at the point of care. They serve as a critical final check for healthcare professionals, especially nurses, before a medication is given to a patient.
This document provides expert recommendations for healthcare professionals on how to diagnose, manage, and understand liver injury caused by prescription drugs, herbal products, and dietary supplements (HDS). It is called a "guidance" instead of a "guideline" because there are very few high-quality randomized controlled trials on this topic; the recommendations are based on...
This document is a European Medicines Agency (EMA) publication, specifically from the Pharmacovigilance Risk Assessment Committee (PRAC). It details new safety information for several medicines, based on recommendations adopted in September 2025.
This document communicates important safety updates for three different categories of products, focusing on new aspects of known risks. Extracts from PRAC – July 2025.
Ciltabtagene autoleucel (Carvykti), Immune-mediated enterocolitis. Brodalumab, Pyoderma gangrenosum. Enzalutamide & Digoxin, Laboratory test interference leading to falsely elevated digoxin levels. Vortioxetine, Hallucinations, not related to serotonin syndrome
Seyraline, multiple acyl-coenzyme A dehydrogenase deficiency(MADD), Sulfamethoxazole, Trimethoprim (Cotrimoxazole), Circulatory shock
Advancing Medication Safety Through Knowledge and Vigilance
